首页> 外文期刊>Gastroenterology Research >Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy
【24h】

Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy

机译:长期甲氨蝶呤治疗溃疡性胰腺炎和多发性肌炎患者结肠中的爱泼斯坦-巴尔病毒阳性弥漫性大B细胞淋巴瘤

获取原文
       

摘要

The link between immunosuppressive therapy and increased lymphoma risk is well established in patients with solid organ transplantation. Epstein-Barr virus-positive (EBV) diffuse large B-cell lymphoma (DLBCL) is known to be a complication in patients receiving methotrexate for rheumatoid arthritis, and the risk of lymphoma in inflammatory bowel disease (IBD) has raised concerns regarding the lymphoproliferative potential of immunomodulatory therapy. In this report, we describe a case of EBV-positive DLBCL arising within the colon of a patient affected by ulcerative pancolitis. The patient is a 73-year-old man with a history of IBD and polymyositis on long-term methotrexate therapy. Increasing age and long-term methotrexate therapy may simulate post-transplantation immunosuppression and contribute to lymphoma tumorigenesis in a segment of chronically inflamed colon.Gastroenterol Res. 2016;9(4-5):83-86doi: http://dx.doi.org/10.14740/gr720e
机译:在实体器官移植患者中,免疫抑制疗法与淋巴瘤风险增加之间的联系已得到充分确立。已知在接受甲氨蝶呤类风湿性关节炎患者中,爱泼斯坦-巴尔病毒阳性(EBV)弥漫性大B细胞淋巴瘤(DLBCL)是一种并发症,炎症性肠病(IBD)中淋巴瘤的风险引起了对淋巴增生的担忧免疫调节疗法的潜力。在本报告中,我们描述了一例受溃疡性胰腺炎影响的患者结肠内出现EBV阳性DLBCL的病例。该患者是一名73岁的男性,长期接受甲氨蝶呤治疗,有IBD和多发性肌炎病史。年龄的增长和长期氨甲蝶呤的治疗可能会模拟移植后的免疫抑制,并在一部分慢性发炎的结肠中促进淋巴瘤的发生。 2016; 9(4-5):83-86doi:http://dx.doi.org/10.14740/gr720e

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号